You are here: Industry Insights > Moderna

News List

Takeda expands COVID-19 vaccine supply in Japan through partnership with Moderna and Government of Japan worldpharmanews
October 30, 2020
Takeda Pharmaceutical Company Limited announced that it will import and distribute 50 million doses of Moderna's COVID-19 vaccine candidate, mRNA-1273, starting in the first half of 2021, pending licensure in Japan. This effort is part of a three-way ...
UK’s MHRA starts rolling review of Moderna’s COVID-19 vaccine pharmatimes
October 29, 2020
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has begun the rolling review process of Moderna’s COVID-19 vaccine candidate, mRNA-1273.
Moderna signs Covid-19 vaccine supply deal with Qatar pharmaceutical-technology
October 29, 2020
Moderna has signed a supply agreement with the Ministry of Public Health of Qatar for its Covid-19 vaccine candidate, mRNA-1273.
Moderna announces supply agreement with the Ministry of Public Health to supply Qatar with mRNA vaccine against COVID-19 (mRNA-1273) worldpharmanews
October 28, 2020
Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced a supply agreement with the Ministry of Public Health of Qatar for mRNA-1273 ..
Moderna completes enrollment of Phase 3 COVE study of mRNA vaccine against COVID-19 (mRNA-1273) worldpharmanews
October 23, 2020
Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced that it has completed enrollment of 30,000 participants for the Phase 3 COVE...
Moderna Completes Enrollment in Phase III COVID-19 Vax Study contractpharma
October 23, 2020
Moderna, Inc. has completed enrollment of 30,000 participants for the Phase 3 COVE study of mRNA-1273, its COVID-19 vaccine candidate, being conducted in collaboration with the National Institutes of Health (NIH) and the Biomedical Advanced Research ...
EMA confirms eligibility for submission of Moderna’s COVID-19 vaccine pharmatimes
October 16, 2020
The European Medicines Agency (EMA) has confirmed that Moderna’s COVID-19 vaccine candidate mRNA-1273 is eligible for submission under the agency’s centralised procedure.
Moderna initiates rolling submission for Covid-19 vaccine pharmaceutical-technology
October 16, 2020
Moderna has initiated a rolling submission to Health Canada for its vaccine candidate against Covid-19, mRNA-1273.
Moderna regains RSV vaccine programme from Merck pharmaceutical-technology
October 12, 2020
Merck (MSD) has returned all rights to a respiratory syncytial virus (RSV) vaccine, mRNA-1172, to Moderna, including rights to develop vaccines against the virus for adults.
Moderna publishes interim results from older adults in phase 1 study of its COVID-19 vaccine expresspharma
October 10, 2020
At the 25 µg and 100 µg dose levels, mRNA-1273 was generally well-tolerated in all age cohorts, neutralizing antibody titers and T cell responses in the 56-70 and 71+ age cohorts were consistent with those reported in younger adults.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 22 23 Next page